Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Detachment | 19 | 2019 | 79 | 3.080 |
Why?
|
| Vitrectomy | 18 | 2012 | 91 | 2.530 |
Why?
|
| Retinopathy of Prematurity | 11 | 2019 | 64 | 2.180 |
Why?
|
| Vitreous Body | 22 | 2008 | 101 | 2.030 |
Why?
|
| Triamcinolone Acetonide | 7 | 2008 | 36 | 1.630 |
Why?
|
| Retina | 11 | 2019 | 499 | 1.540 |
Why?
|
| Retinal Perforations | 6 | 2019 | 25 | 1.450 |
Why?
|
| Endophthalmitis | 8 | 2008 | 69 | 1.250 |
Why?
|
| Laser Coagulation | 6 | 2010 | 128 | 0.990 |
Why?
|
| Lens, Crystalline | 7 | 2012 | 113 | 0.980 |
Why?
|
| Visual Acuity | 15 | 2019 | 705 | 0.980 |
Why?
|
| Injections | 14 | 2008 | 156 | 0.970 |
Why?
|
| Glucocorticoids | 5 | 2007 | 401 | 0.890 |
Why?
|
| Electroretinography | 8 | 2010 | 123 | 0.810 |
Why?
|
| Refraction, Ocular | 2 | 2010 | 217 | 0.590 |
Why?
|
| Anti-Infective Agents | 4 | 2008 | 269 | 0.570 |
Why?
|
| Aza Compounds | 3 | 2006 | 15 | 0.550 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2011 | 219 | 0.510 |
Why?
|
| Antifungal Agents | 5 | 2010 | 306 | 0.510 |
Why?
|
| Quinolines | 3 | 2006 | 112 | 0.510 |
Why?
|
| Fluoroquinolones | 5 | 2006 | 90 | 0.500 |
Why?
|
| Eye Infections, Fungal | 3 | 2008 | 73 | 0.500 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2008 | 78 | 0.490 |
Why?
|
| Eye Infections, Bacterial | 3 | 2008 | 86 | 0.480 |
Why?
|
| Aqueous Humor | 6 | 2006 | 28 | 0.460 |
Why?
|
| Retinal Vein Occlusion | 2 | 2008 | 27 | 0.460 |
Why?
|
| Triazoles | 3 | 2004 | 142 | 0.450 |
Why?
|
| Retinal Diseases | 4 | 2006 | 180 | 0.400 |
Why?
|
| Fluorescein Angiography | 7 | 2019 | 152 | 0.400 |
Why?
|
| Myopia | 2 | 2010 | 132 | 0.390 |
Why?
|
| Pyrimidines | 3 | 2004 | 417 | 0.380 |
Why?
|
| Rabbits | 7 | 2008 | 730 | 0.370 |
Why?
|
| Macular Degeneration | 4 | 2008 | 127 | 0.350 |
Why?
|
| Retinal Hemorrhage | 3 | 2011 | 26 | 0.350 |
Why?
|
| Vitreous Detachment | 2 | 2007 | 11 | 0.340 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2007 | 14 | 0.330 |
Why?
|
| Suture Techniques | 2 | 2008 | 187 | 0.330 |
Why?
|
| Ectopia Lentis | 1 | 2008 | 12 | 0.290 |
Why?
|
| Bacillus cereus | 1 | 2008 | 11 | 0.290 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2008 | 216 | 0.290 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2008 | 39 | 0.290 |
Why?
|
| Cryotherapy | 2 | 2006 | 21 | 0.290 |
Why?
|
| Postoperative Complications | 7 | 2009 | 3155 | 0.290 |
Why?
|
| Iris | 1 | 2008 | 50 | 0.290 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2008 | 364 | 0.280 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 137 | 0.280 |
Why?
|
| Retrospective Studies | 19 | 2019 | 17380 | 0.270 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2006 | 2 | 0.260 |
Why?
|
| Benzyl Alcohol | 1 | 2006 | 2 | 0.260 |
Why?
|
| Retinal Neovascularization | 1 | 2006 | 17 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2011 | 446 | 0.260 |
Why?
|
| Gestational Age | 7 | 2006 | 1216 | 0.250 |
Why?
|
| Telangiectasis | 1 | 2006 | 10 | 0.250 |
Why?
|
| Fovea Centralis | 1 | 2006 | 10 | 0.250 |
Why?
|
| Tomography, Optical Coherence | 4 | 2017 | 561 | 0.250 |
Why?
|
| Phacoemulsification | 2 | 2005 | 147 | 0.250 |
Why?
|
| Retinal Vessels | 2 | 2003 | 78 | 0.250 |
Why?
|
| Cat-Scratch Disease | 1 | 2005 | 32 | 0.240 |
Why?
|
| Lenses, Intraocular | 1 | 2008 | 277 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 1068 | 0.230 |
Why?
|
| Infant, Newborn | 11 | 2012 | 8586 | 0.230 |
Why?
|
| Male | 30 | 2019 | 65692 | 0.220 |
Why?
|
| Triamcinolone | 1 | 2004 | 14 | 0.220 |
Why?
|
| Treatment Outcome | 12 | 2012 | 12974 | 0.210 |
Why?
|
| Photochemotherapy | 1 | 2003 | 44 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2012 | 5455 | 0.210 |
Why?
|
| Humans | 42 | 2019 | 133414 | 0.200 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2006 | 178 | 0.190 |
Why?
|
| Papilledema | 1 | 2003 | 87 | 0.190 |
Why?
|
| Aged | 15 | 2019 | 21609 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2006 | 826 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 4 | 2008 | 2509 | 0.190 |
Why?
|
| Choroid | 2 | 2017 | 41 | 0.180 |
Why?
|
| Osmolar Concentration | 3 | 2008 | 179 | 0.180 |
Why?
|
| Mitosporic Fungi | 1 | 2001 | 8 | 0.180 |
Why?
|
| Female | 24 | 2019 | 71463 | 0.180 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2001 | 17 | 0.180 |
Why?
|
| Prednisolone | 1 | 2001 | 79 | 0.170 |
Why?
|
| Alcaligenes | 1 | 2000 | 3 | 0.170 |
Why?
|
| Propionibacterium acnes | 1 | 2000 | 13 | 0.170 |
Why?
|
| Retinal Artery Occlusion | 1 | 2000 | 15 | 0.170 |
Why?
|
| Biological Availability | 4 | 2006 | 153 | 0.170 |
Why?
|
| Pseudophakia | 1 | 2000 | 44 | 0.170 |
Why?
|
| Disease Progression | 4 | 2019 | 2237 | 0.170 |
Why?
|
| Keratitis | 1 | 2001 | 110 | 0.160 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2000 | 56 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2000 | 88 | 0.160 |
Why?
|
| Mycoses | 1 | 2001 | 119 | 0.160 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 7160 | 0.160 |
Why?
|
| Eye Diseases, Hereditary | 1 | 1999 | 33 | 0.150 |
Why?
|
| Acute Disease | 3 | 2007 | 1190 | 0.150 |
Why?
|
| Postoperative Period | 2 | 2009 | 341 | 0.140 |
Why?
|
| Animals | 12 | 2010 | 36379 | 0.140 |
Why?
|
| Fundus Oculi | 3 | 2019 | 67 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2004 | 2899 | 0.140 |
Why?
|
| Half-Life | 2 | 2008 | 160 | 0.130 |
Why?
|
| Adult | 13 | 2019 | 31787 | 0.130 |
Why?
|
| Intraocular Pressure | 2 | 2008 | 136 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 1310 | 0.130 |
Why?
|
| Choroidal Neovascularization | 2 | 2008 | 34 | 0.120 |
Why?
|
| Voriconazole | 3 | 2004 | 34 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 551 | 0.120 |
Why?
|
| Exudates and Transudates | 3 | 2011 | 22 | 0.120 |
Why?
|
| Middle Aged | 12 | 2019 | 29213 | 0.120 |
Why?
|
| Birth Weight | 2 | 2006 | 352 | 0.110 |
Why?
|
| Blindness | 2 | 2008 | 76 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2015 | 3642 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1306 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 208 | 0.100 |
Why?
|
| Rats | 3 | 2004 | 3883 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 186 | 0.100 |
Why?
|
| Resuscitation | 1 | 2015 | 268 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2004 | 727 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1734 | 0.090 |
Why?
|
| Bevacizumab | 2 | 2011 | 79 | 0.090 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2011 | 8 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 1193 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 414 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2012 | 14789 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2015 | 376 | 0.080 |
Why?
|
| Echinocandins | 1 | 2010 | 44 | 0.080 |
Why?
|
| Incidence | 3 | 2007 | 3396 | 0.080 |
Why?
|
| Bacteria | 2 | 2005 | 533 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 106 | 0.080 |
Why?
|
| Critical Care | 1 | 2015 | 693 | 0.080 |
Why?
|
| Sulfur Hexafluoride | 1 | 2008 | 4 | 0.080 |
Why?
|
| Epiretinal Membrane | 1 | 2008 | 14 | 0.080 |
Why?
|
| Child | 6 | 2019 | 25734 | 0.070 |
Why?
|
| Time Factors | 4 | 2019 | 6570 | 0.070 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 40 | 0.070 |
Why?
|
| Vancomycin | 2 | 2008 | 235 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 120 | 0.070 |
Why?
|
| Posture | 1 | 2008 | 157 | 0.070 |
Why?
|
| Eye | 1 | 2009 | 245 | 0.070 |
Why?
|
| Risk Factors | 4 | 2007 | 11085 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2007 | 5 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2009 | 227 | 0.070 |
Why?
|
| Ceftazidime | 1 | 2008 | 49 | 0.070 |
Why?
|
| Citrus | 1 | 2007 | 7 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1969 | 0.070 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 43 | 0.070 |
Why?
|
| Cataract | 1 | 2008 | 174 | 0.070 |
Why?
|
| Macular Edema | 2 | 2006 | 92 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 1100 | 0.070 |
Why?
|
| Dark Adaptation | 1 | 2006 | 36 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 70 | 0.070 |
Why?
|
| Aphakia, Postcataract | 1 | 2006 | 18 | 0.060 |
Why?
|
| Serpins | 1 | 2006 | 34 | 0.060 |
Why?
|
| Candidiasis | 1 | 2007 | 138 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2006 | 76 | 0.060 |
Why?
|
| Silicone Oils | 1 | 2005 | 8 | 0.060 |
Why?
|
| Vision, Ocular | 1 | 2006 | 133 | 0.060 |
Why?
|
| Photic Stimulation | 1 | 2006 | 235 | 0.060 |
Why?
|
| Bartonella henselae | 1 | 2005 | 19 | 0.060 |
Why?
|
| Florida | 1 | 2005 | 79 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 315 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2006 | 6570 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 9854 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2005 | 59 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 204 | 0.060 |
Why?
|
| Neuroglia | 1 | 2007 | 217 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 104 | 0.060 |
Why?
|
| Photography | 1 | 2005 | 88 | 0.060 |
Why?
|
| Eye Proteins | 1 | 2006 | 233 | 0.060 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 90 | 0.060 |
Why?
|
| Porphyrins | 1 | 2003 | 18 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2004 | 270 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2003 | 78 | 0.050 |
Why?
|
| Gases | 1 | 2003 | 20 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 38 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2003 | 62 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 22 | 0.050 |
Why?
|
| Enterococcus faecium | 1 | 2003 | 19 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 484 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 405 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1760 | 0.050 |
Why?
|
| Necrosis | 1 | 2003 | 221 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 375 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 703 | 0.050 |
Why?
|
| Spherocytes | 1 | 2002 | 2 | 0.050 |
Why?
|
| Scleral Buckling | 1 | 2002 | 14 | 0.050 |
Why?
|
| Lens Subluxation | 1 | 2002 | 3 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2006 | 970 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 614 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2006 | 733 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 82 | 0.040 |
Why?
|
| Corneal Injuries | 1 | 2001 | 36 | 0.040 |
Why?
|
| Cataract Extraction | 1 | 2002 | 155 | 0.040 |
Why?
|
| Debridement | 1 | 2001 | 91 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2002 | 321 | 0.040 |
Why?
|
| Intravitreal Injections | 2 | 2011 | 148 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 15 | 0.040 |
Why?
|
| Eye Neoplasms | 1 | 2000 | 53 | 0.040 |
Why?
|
| Ophthalmology | 1 | 2002 | 198 | 0.040 |
Why?
|
| Microphthalmos | 1 | 1999 | 58 | 0.040 |
Why?
|
| Bacteremia | 1 | 2003 | 418 | 0.040 |
Why?
|
| Hyperplasia | 1 | 1999 | 202 | 0.040 |
Why?
|
| Device Removal | 1 | 2000 | 219 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 20505 | 0.030 |
Why?
|
| Infarction | 1 | 2017 | 24 | 0.030 |
Why?
|
| Biomarkers | 1 | 2007 | 3424 | 0.030 |
Why?
|
| Texas | 1 | 2005 | 3688 | 0.030 |
Why?
|
| Macula Lutea | 1 | 2017 | 48 | 0.030 |
Why?
|
| Giant Cell Arteritis | 1 | 2017 | 59 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 58 | 0.030 |
Why?
|
| Infant | 2 | 2012 | 13159 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1999 | 997 | 0.030 |
Why?
|
| Vitreous Hemorrhage | 2 | 2005 | 9 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 903 | 0.020 |
Why?
|
| Subretinal Fluid | 1 | 2011 | 11 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2002 | 1245 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2015 | 508 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 1814 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2010 | 36 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 159 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2210 | 0.020 |
Why?
|
| Retinal Ganglion Cells | 1 | 2010 | 120 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 4822 | 0.020 |
Why?
|
| Beverages | 1 | 2007 | 102 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2006 | 30 | 0.020 |
Why?
|
| Urine | 1 | 2006 | 83 | 0.020 |
Why?
|
| Sputum | 1 | 2006 | 117 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 5176 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 483 | 0.010 |
Why?
|
| Fungi | 1 | 2004 | 75 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 369 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 50 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2006 | 610 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2002 | 48 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 102 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 376 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 18911 | 0.010 |
Why?
|
| Choroid Neoplasms | 1 | 2000 | 25 | 0.010 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2000 | 19 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 236 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 342 | 0.010 |
Why?
|
| Reoperation | 1 | 2002 | 852 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 836 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2002 | 1063 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1349 | 0.010 |
Why?
|